Article info

Download PDFPDF
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study

Authors

  1. Correspondence to Dr Léo Plaçais, Médecine Interne, Hospital Bicetre, Le Kremlin-Bicetre 94270, France; leoplacais{at}gmail.com
View Full Text

Citation

Plaçais L, Dalle S, Dereure O, et al
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study

Publication history

  • Received January 28, 2022
  • Accepted June 15, 2022
  • First published July 4, 2022.
Online issue publication 
September 12, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.